HK1072248A1 - Substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimides and method of reducing tnf alpha levels - Google Patents

Substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimides and method of reducing tnf alpha levels

Info

Publication number
HK1072248A1
HK1072248A1 HK05102027A HK05102027A HK1072248A1 HK 1072248 A1 HK1072248 A1 HK 1072248A1 HK 05102027 A HK05102027 A HK 05102027A HK 05102027 A HK05102027 A HK 05102027A HK 1072248 A1 HK1072248 A1 HK 1072248A1
Authority
HK
Hong Kong
Prior art keywords
carbon atoms
hydrogen
alkyl
dioxopiperidin
phthalimides
Prior art date
Application number
HK05102027A
Other languages
English (en)
Inventor
George W Muller
David I Stirling
Roger Shen-Chu Chen
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of HK1072248A1 publication Critical patent/HK1072248A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
HK05102027A 1997-05-30 2005-03-08 Substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimides and method of reducing tnf alpha levels HK1072248A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4827897P 1997-05-30 1997-05-30

Publications (1)

Publication Number Publication Date
HK1072248A1 true HK1072248A1 (en) 2005-08-19

Family

ID=21953674

Family Applications (1)

Application Number Title Priority Date Filing Date
HK05102027A HK1072248A1 (en) 1997-05-30 2005-03-08 Substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimides and method of reducing tnf alpha levels

Country Status (25)

Country Link
US (3) US6395754B1 (fr)
EP (3) EP1486496B1 (fr)
JP (2) JP4307567B2 (fr)
KR (1) KR100526212B1 (fr)
CN (3) CN1258293A (fr)
AT (2) ATE401319T1 (fr)
AU (1) AU741982B2 (fr)
CA (2) CA2291218C (fr)
CY (1) CY1108348T1 (fr)
CZ (1) CZ299812B6 (fr)
DE (2) DE69825994T2 (fr)
DK (2) DK1486496T3 (fr)
ES (3) ES2229497T3 (fr)
FI (1) FI19992490A (fr)
HK (1) HK1072248A1 (fr)
HU (2) HU228769B1 (fr)
MC (1) MC225A7 (fr)
NO (6) NO322080B1 (fr)
NZ (1) NZ501429A (fr)
PL (1) PL193276B1 (fr)
PT (2) PT984955E (fr)
RU (1) RU2209207C2 (fr)
SK (1) SK163099A3 (fr)
TR (4) TR201005282T2 (fr)
WO (1) WO1998054170A1 (fr)

Families Citing this family (153)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6228879B1 (en) 1997-10-16 2001-05-08 The Children's Medical Center Methods and compositions for inhibition of angiogenesis
US6429221B1 (en) 1994-12-30 2002-08-06 Celgene Corporation Substituted imides
US6518281B2 (en) * 1995-08-29 2003-02-11 Celgene Corporation Immunotherapeutic agents
HU228769B1 (en) * 1996-07-24 2013-05-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
US5635517B1 (en) 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
PT1308444E (pt) * 1997-11-18 2006-08-31 Celgene Corp 2-( 2,6-dioxo-3-fluoropiperidina-3-il )- isoindolinas e a sua utilizacao para reduzir os niveis de tnf
US5955476A (en) * 1997-11-18 1999-09-21 Celgene Corporation Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels
TR200101503T2 (tr) * 1998-03-16 2002-06-21 Celgene Corporation 2-(2,6-dioksopiperidin-3-il) izoindolin türevleri, bunların hazırlanması ve enflamatuar sitokinlerin inhibitörleri olarak kullanımı
AU771015B2 (en) 1999-03-18 2004-03-11 Celgene Corporation Substituted 1-oxo- and 1,3-dioxoisoindolines and their use in pharmaceutical compositions for reducing inflammatory cytokine levels
US7629360B2 (en) 1999-05-07 2009-12-08 Celgene Corporation Methods for the treatment of cachexia and graft v. host disease
US6458810B1 (en) 2000-11-14 2002-10-01 George Muller Pharmaceutically active isoindoline derivatives
JP4242651B2 (ja) * 2000-11-30 2009-03-25 ザ チルドレンズ メディカル センター コーポレイション ４−アミノ−サリドマイドエナンチオマーの合成法
US7091353B2 (en) 2000-12-27 2006-08-15 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
US20030045552A1 (en) * 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
US7498171B2 (en) 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
JP2005536189A (ja) * 2002-04-12 2005-12-02 セルジーン・コーポレーション 血管新生のモジュレーターの同定方法、それにより見出された化合物および該化合物を使用する治療方法
US20100129363A1 (en) * 2002-05-17 2010-05-27 Zeldis Jerome B Methods and compositions using pde4 inhibitors for the treatment and management of cancers
US7393862B2 (en) 2002-05-17 2008-07-01 Celgene Corporation Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
USRE48890E1 (en) 2002-05-17 2022-01-11 Celgene Corporation Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation
US7323479B2 (en) * 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
WO2003097052A2 (fr) 2002-05-17 2003-11-27 Celgene Corporation Methodes et compositions faisant appel a des composes immunomodulateurs pour le traitement et la prise en charge des cancers et d'autres maladies
US7968569B2 (en) 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
EP1556033A4 (fr) * 2002-05-17 2006-05-31 Celgene Corp Methodes et compositions mettant en oeuvre des medicaments selectifs inhibiteurs des cytokines pour le traitement et la prise en charge des cancers et autres maladies
US8404716B2 (en) 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US7189740B2 (en) 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
EP1900369A1 (fr) 2002-10-15 2008-03-19 Celgene Corporation Procédé d'utilisation et compositions comprenant des composés immunomodulateurs pour le traitement et la gestion de syndromes myélodysplasiques
US8404717B2 (en) * 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes using lenalidomide
ZA200503024B (en) * 2002-10-15 2006-11-29 Celgene Corp Selective cytokine inhibitory drugs for treating myelodysplastic syndrome
US11116782B2 (en) 2002-10-15 2021-09-14 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US20040087558A1 (en) * 2002-10-24 2004-05-06 Zeldis Jerome B. Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
US20050203142A1 (en) * 2002-10-24 2005-09-15 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
KR20050057672A (ko) * 2002-10-24 2005-06-16 셀진 코포레이션 통증의 치료, 변형 및 관리를 위한 면역조절 화합물을포함하는 조성물 및 이의 사용 방법
CA2504024A1 (fr) * 2002-10-31 2004-05-21 Celgene Corporation Compositions comprenant des composes immunomodulateurs pour le traitement et la gestion d'une degeneration maculaire, ainsi que leurs methodes d'utilisation
US20040091455A1 (en) * 2002-10-31 2004-05-13 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration
US7563810B2 (en) * 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
NZ564480A (en) 2002-11-06 2008-12-24 Celgene Corp Use of selective cytokine inhibitory drugs for the treatment of Behcet's disease
US8034831B2 (en) * 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
BR0316256A (pt) * 2002-11-18 2005-10-04 Celgene Corp Métodos de inibir a produção de tnf-alfa e a atividade de pde4, de tratar ou prevenir uma doença ou um distúrbio, de controlar os nìveis de camp em uma célula e de produzir um composto, composição farmacêutica e composto
JP2006510617A (ja) * 2002-11-18 2006-03-30 セルジーン・コーポレーション （＋）−３−（３，４−ジメトキシ−フェニル）−３−（１−オキソ−１，３−ジヒドロ−イソインドール−２−イル）−プロピオンアミドの使用方法およびそれを含む組成物
US7320992B2 (en) 2003-08-25 2008-01-22 Amgen Inc. Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use
UA83504C2 (en) 2003-09-04 2008-07-25 Селджин Корпорейшн Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
US20080027113A1 (en) * 2003-09-23 2008-01-31 Zeldis Jerome B Methods of Using and Compositions Comprising Immunomodulatory Compounds for Treatment and Management of Macular Degeneration
US7612096B2 (en) * 2003-10-23 2009-11-03 Celgene Corporation Methods for treatment, modification and management of radiculopathy using 1-oxo-2-(2,6-dioxopiperidin-3yl)-4-aminoisoindoline
JP2007510670A (ja) * 2003-11-06 2007-04-26 セルジーン・コーポレーション サリドマイドを用いた、癌、及び他の疾患を治療、及び管理する方法ならびに組成物
US20050100529A1 (en) * 2003-11-06 2005-05-12 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
EP1692128A1 (fr) 2003-11-19 2006-08-23 Signal Pharmaceuticals LLC Composes d'indazole et leurs procedes d'utilisation en tant qu'inhibiteurs de la proteine kinase
US20050143344A1 (en) * 2003-12-30 2005-06-30 Zeldis Jerome B. Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases
CN1956718A (zh) * 2004-03-22 2007-05-02 细胞基因公司 用于治疗和控制皮肤疾病和病症的含免疫调节化合物的组合物和使用方法
US20050222209A1 (en) * 2004-04-01 2005-10-06 Zeldis Jerome B Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease
CA2563207A1 (fr) * 2004-04-14 2005-11-24 Celgene Corporation Procedes d'utilisation et compositions comprenant des medicaments d'inhibition selective de cytokine, pour traiter et controler des syndromes myelodysplasiques
MXPA06011798A (es) * 2004-04-14 2007-01-16 Celgene Corp Metodos de uso y composiciones que comprenden compuestos inmunomoduladores para el tratamiento y manejo de sindromes mielodisplasticos.
BRPI0510110A (pt) * 2004-04-23 2007-09-25 Celgene Corp método para tratar, prevenir ou controlar hipertensão pulmonar, e, composição farmacêutica
CN1984657B (zh) * 2004-05-05 2010-12-15 细胞基因公司 用于治疗和控制骨髓增生性疾病的包含免疫调节化合物的组合物和使用方法
WO2006028964A1 (fr) 2004-09-03 2006-03-16 Celgene Corporation Procedes de preparation de 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines substituees
AU2005302523A1 (en) * 2004-10-28 2006-05-11 Celgene Corporation Methods and compositions using PDE4 modulators for treatment and management of central nervous system injury
BRPI0518282A2 (pt) * 2004-11-23 2008-11-11 Celgene Corp uso de uma quantidade terapeuticamente ou profilaticamente efetiva de um composto imunomodulatàrio
WO2006081251A2 (fr) * 2005-01-25 2006-08-03 Celgene Corporation Methodes et compositions utilisant 4-amino-2-(3-methyl-2,6-dioxopiperidin-3-yl)-isoindole-1-3-dione
CN100383139C (zh) * 2005-04-07 2008-04-23 天津和美生物技术有限公司 可抑制细胞释放肿瘤坏死因子的哌啶-2，6-二酮衍生物
US20060270707A1 (en) * 2005-05-24 2006-11-30 Zeldis Jerome B Methods and compositions using 4-[(cyclopropanecarbonylamino)methyl]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione for the treatment or prevention of cutaneous lupus
EP1901789A2 (fr) * 2005-06-30 2008-03-26 Anthrogenesis Corporation Reparation de la membrane du tympan a l'aide de tissu biologique de collagene derive du placenta
PT2380887E (pt) * 2005-06-30 2013-09-18 Celgene Corp Processos para a preparação de compostos de 4-amino-2-(2,6-dioxopiperidin-3-il)isoindolina-1,3-diona
EP1919500A2 (fr) 2005-07-13 2008-05-14 Anthrogenesis Corporation Traitement d'ulceres de la jambe a l'aide d'un tissu biologique a base de collagene derive de placenta
EP1919365A2 (fr) * 2005-07-13 2008-05-14 Anthrogenesis Corporation Obturateur oculaire forme a partir dun tissu biologique a base de collagene derive du placenta
ES2434946T3 (es) 2005-08-31 2013-12-18 Celgene Corporation Compuestos de isoindol imida y composiciones que los comprenden y métodos para usarlo
EP2301535B1 (fr) 2005-09-01 2014-05-28 Celgene Corporation Utilisation immunologique de composés immunomodulateurs comme vaccin et thérapie pour des maladies infectieuses
US20070066512A1 (en) * 2005-09-12 2007-03-22 Dominique Verhelle Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels
US20080138295A1 (en) * 2005-09-12 2008-06-12 Celgene Coporation Bechet's disease using cyclopropyl-N-carboxamide
CN1939922B (zh) * 2005-09-27 2010-10-13 天津和美生物技术有限公司 可抑制细胞释放肿瘤坏死因子的5H-噻吩[3，4-c]吡咯-4，6-二酮衍生物
PE20070771A1 (es) 2005-10-13 2007-08-11 Anthrogenesis Corp Inmunomodulacion mediante el uso de celulas madres de la placenta
US20070155791A1 (en) * 2005-12-29 2007-07-05 Zeldis Jerome B Methods for treating cutaneous lupus using aminoisoindoline compounds
KR20080097190A (ko) 2005-12-29 2008-11-04 안트로제네시스 코포레이션 태반 줄기세포의 수집과 보존을 위한 개선된 조성물과 이조성물의 이용 방법
WO2007136640A2 (fr) * 2006-05-16 2007-11-29 Celgene Corporation Procédé de préparation de 2-(2,6-dioxopipéridin-3-yl)isoindole-1,3-dione substitué
CL2007002218A1 (es) 2006-08-03 2008-03-14 Celgene Corp Soc Organizada Ba Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa.
US8105634B2 (en) 2006-08-15 2012-01-31 Anthrogenesis Corporation Umbilical cord biomaterial for medical use
WO2008027542A2 (fr) * 2006-08-30 2008-03-06 Celgene Corporation Composés d'isoindoline substituée en 5
US8877780B2 (en) 2006-08-30 2014-11-04 Celgene Corporation 5-substituted isoindoline compounds
RU2448101C2 (ru) * 2006-08-30 2012-04-20 Селджин Корпорейшн 5-замещенные изоиндолиновые соединения
DK2420497T3 (en) 2006-09-26 2016-03-07 Celgene Corp 5-substituted quinazolinone derivatives as anticancer agents
WO2008042441A1 (fr) * 2006-10-03 2008-04-10 Anthrogenesis Corporation Utilisation de biomatériau de cordon ombilical en chirurgie oculaire
US8071135B2 (en) 2006-10-04 2011-12-06 Anthrogenesis Corporation Placental tissue compositions
EP2664341A3 (fr) * 2006-10-06 2014-01-08 Anthrogenesis Corporation Compositions de collagène placentaire (télopeptide) natif
CN101186611B (zh) * 2006-11-15 2011-05-18 天津和美生物技术有限公司 可抑制细胞释放肿瘤坏死因子的吡咯啉-2-酮衍生物及其制备和应用
NZ597779A (en) 2007-02-12 2013-07-26 Anthrogenesis Corp Treatment of inflammatory diseases using placental stem cells
CN101688177A (zh) * 2007-02-12 2010-03-31 人类起源公司 来自贴壁胎盘干细胞的肝细胞和软骨细胞；以及cd34+、cd45-胎盘干细胞富集的细胞群
WO2009020590A1 (fr) 2007-08-07 2009-02-12 Celgene Corporation Procédés de traitement de lymphomes chez certaines populations de patients et criblage de patients pour ladite thérapie
WO2009042177A1 (fr) 2007-09-26 2009-04-02 Celgene Corporation Dérivés de quinazolinone substitués en position 6, 7 ou 8, compositions les contenant et procédés d'utilisation
SI2203176T1 (sl) 2007-09-28 2015-04-30 Anthrogenesis Corporation Tumorska supresija z uporabo humanega perfuzata placente in intermediarnih naravnih celic ubijalk, pridobljenih iz humane placente
CA2710196A1 (fr) 2007-12-20 2009-07-09 Celgene Corporation Utilisation d'un micro-arn a titre de marqueur biologique d'une activite medicamenteuse immunomodulatoire
US20090232796A1 (en) * 2008-02-20 2009-09-17 Corral Laura G Method of treating cancer by administering an immunomodulatory compound in combination with a cd40 antibody or cd40 ligand
PE20140963A1 (es) 2008-10-29 2014-08-06 Celgene Corp Compuestos de isoindolina para el tratamiento de cancer
WO2010093434A1 (fr) 2009-02-11 2010-08-19 Celgene Corporation Isotopologues de lénalidomide
PT2411506T (pt) 2009-03-25 2019-03-19 Celularity Inc Supressão de tumores usando células assassinas naturais intermédias derivadas de placenta humana e compostos imunomoduladores
PT2391355T (pt) 2009-05-19 2017-02-21 Celgene Corp Formulações de 4-amino-2-(2,6-dioxopiperidin-3-il)isoindolino-1,3-diona
WO2010137547A1 (fr) 2009-05-25 2010-12-02 国立大学法人東京工業大学 Composition pharmaceutique contenant un facteur nucléaire impliqué dans la prolifération et la différentiation de cellules neuronales centrales
CN101696205B (zh) 2009-11-02 2011-10-19 南京卡文迪许生物工程技术有限公司 3-(取代二氢异吲哚-2-基)-2,6-哌啶二酮多晶型物和药用组合物
AU2010333767A1 (en) 2009-12-22 2012-07-05 Celgene Corporation (Methylsulfonyl) ethyl benzene isoindoline derivatives and their therapeutical uses
MX337566B (es) 2010-01-05 2016-03-10 Celgene Corp Combinación de un compuesto inmunomodulador y una artemisinina o un derivado de ésta para tratar cáncer.
RS58523B1 (sr) 2010-02-11 2019-04-30 Celgene Corp Derivati arilmetoksi izoindolina i kombinacije koje ih obuhvataju i postupci njihove upotrebe
CA2794096A1 (fr) 2010-04-07 2011-10-13 Celgene Corporation Methodes de traitement d'une infection respiratoire d'origine virale
WO2012078492A1 (fr) 2010-12-06 2012-06-14 Celgene Corporation Traitement d'association avec du lénalidomide et un inhibiteur de cdk pour traiter le myélome multiple
WO2012092485A1 (fr) 2010-12-31 2012-07-05 Anthrogenesis Corporation Amélioration de l'efficacité de cellules souches placentaires sous l'effet de molécules d'arn modulateur
US8853175B2 (en) 2011-01-10 2014-10-07 Celgene Corporation Phenethylsulfone isoindoline derivatives and their use
MX2013010360A (es) 2011-03-11 2014-04-14 Celgene Corp Formas solidas sde 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-pi peridin-2,6-diona, y sus composiciones farmaceuticas y usos.
EP2699091B1 (fr) 2011-03-28 2017-06-21 DeuteRx, LLC Composés de 2',6'-dioxo-3'-deutéro-pipéridin-3-yl-isoindoline
JP2014517915A (ja) 2011-04-18 2014-07-24 セルジーン コーポレイション 多発性骨髄腫治療のためのバイオマーカー
AU2012249491B2 (en) 2011-04-29 2016-12-15 Celgene Corporation Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
AU2012262273B2 (en) 2011-06-01 2017-09-14 Celularity Inc. Treatment of pain using placental stem cells
US20140221427A1 (en) 2011-06-22 2014-08-07 Celgene Corporation Isotopologues of pomalidomide
SG11201400632YA (en) 2011-09-14 2014-04-28 Celgene Corp Formulations of cyclopropanecarboxylic acid {2-(1s)-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1h-isoindol-4-yl}-amidecelgene corporation state of incorporation:delaware
EP3756650A1 (fr) 2011-12-27 2020-12-30 Amgen (Europe) GmbH Formulations de (+)-2-[1-(3-éthoxy-4-méthoxy-phényl)-2-méthanesulfonyl-éthyl]-4-acétylaminoisoindoline-1,3-dione
WO2013182662A1 (fr) 2012-06-06 2013-12-12 Bionor Immuno As Vaccin
WO2014004990A2 (fr) 2012-06-29 2014-01-03 Celgene Corporation Procédés pour déterminer l'efficacité d'un médicament en utilisant des protéines associées au céréblon
ES2755748T3 (es) 2012-07-27 2020-04-23 Celgene Corp Procedimientos para preparar compuestos de isoindolin-1,3-diona
CA2878954C (fr) 2012-08-09 2020-12-08 Benjamin M. Cohen Sels et formes solides de la (s)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione et des compositions les comprenant et ses procedes d'utilisation
US9587281B2 (en) 2012-08-14 2017-03-07 Celgene Corporation Cereblon isoforms and their use as biomarkers for therapeutic treatment
KR20150054962A (ko) 2012-09-10 2015-05-20 셀진 코포레이션 국소 진행성 유방암의 치료방법
US9540340B2 (en) 2013-01-14 2017-01-10 Deuterx, Llc 3-(5-substituted-4-oxoquinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives and compositions comprising and methods of using the same
EP2953635A4 (fr) 2013-02-05 2016-10-26 Anthrogenesis Corp Cellules tueuses naturelles provenant du placenta
EP2764866A1 (fr) 2013-02-07 2014-08-13 IP Gesellschaft für Management mbH Inhibiteurs de l'enzyme activant nedd8
EP2968334A4 (fr) 2013-03-14 2016-08-03 Deuterx Llc Dérivés de 3-(oxoquinazolin-3(4h)-yl-4 substitué)-3-deutéro-pipéridine-2,6-dione et des compositions les comprenant et des procédés les utilisant
US20140314752A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Methods for treating cancer using tor kinase inhibitor combination therapy
WO2015007337A1 (fr) 2013-07-19 2015-01-22 Bionor Immuno As Procédé de vaccination contre le vih
JP6640126B2 (ja) 2014-06-27 2020-02-05 セルジーン コーポレイション セレブロン及び他のｅ３ユビキチンリガーゼの立体構造の変化を誘導するための組成物及び方法
RS64038B1 (sr) 2014-08-22 2023-04-28 Celgene Corp Postupci za lečenje multiplog mijeloma imunomodulatornim jedinjenjima u kombinaciji sa antitelima
PT3643709T (pt) 2014-10-30 2021-12-20 Kangpu Biopharmaceuticals Ltd Derivado, intermediário, método de preparação, composição farmacêutica de isoindolina e utilização dos mesmos
EP3313818B1 (fr) 2015-06-26 2023-11-08 Celgene Corporation Procédés pour le traitement du sarcome de kaposi ou le lymphome induit par le kshv à l'aide de composés immunomodulateurs et utilisations de biomarqueurs
US9809603B1 (en) 2015-08-18 2017-11-07 Deuterx, Llc Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same
WO2017117118A1 (fr) 2015-12-28 2017-07-06 Celgene Corporation Compositions et méthodes pour induire des modifications conformationnelles dans céréblon et d'autres ubiquitine ligases e3
ITUB20169994A1 (it) 2016-01-14 2017-07-14 Phf Sa Nuove forme cristalline di farmaci immunomodulatori
WO2018102786A1 (fr) 2016-12-03 2018-06-07 Juno Therapeutics, Inc. Procédés de modulation de lymphocytes t modifiés par car
IL310031A (en) 2017-05-01 2024-03-01 Juno Therapeutics Inc A combination of cellular therapy and an immune modulatory compound
AU2018275894A1 (en) 2017-06-02 2019-12-12 Juno Therapeutics, Inc. Articles of manufacture and methods for treatment using adoptive cell therapy
CA3067602A1 (fr) 2017-06-29 2019-01-03 Juno Therapeutics, Inc. Modele murin pour evaluer des toxicites associees a des immunotherapies
US20200246393A1 (en) 2017-09-28 2020-08-06 Celularity, Inc. Tumor suppression using human placenta-derived intermediate natural killer (pink) cells in combination with an antibody
WO2019089858A2 (fr) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Procédés d'évaluation ou de surveillance d'une réponse à une thérapie cellulaire
US11623961B2 (en) 2017-11-01 2023-04-11 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for B-cell maturation antigen
EP3710002A4 (fr) 2017-11-16 2021-07-07 C4 Therapeutics, Inc. Agents de dégradation et dégrons pour dégradation protéique ciblée
WO2019118937A1 (fr) 2017-12-15 2019-06-20 Juno Therapeutics, Inc. Molécules de liaison à l'anti-cct5 et procédés d'utilisation associés
US11401336B2 (en) 2018-02-21 2022-08-02 Celgene Corporation BCMA-binding antibodies and uses thereof
KR20210018199A (ko) 2018-03-26 2021-02-17 씨4 테라퓨틱스, 인코포레이티드 이카로스의 분해를 위한 세레블론 결합제
WO2019204354A1 (fr) 2018-04-16 2019-10-24 C4 Therapeutics, Inc. Composés spirocycliques
EP3846800A4 (fr) 2018-09-04 2022-08-24 C4 Therapeutics, Inc. Composés pour la dégradation de brd9 ou mth1
US20220008477A1 (en) 2018-11-08 2022-01-13 Juno Therapeutics, Inc. Methods and combinations for treatment and t cell modulation
WO2020102195A1 (fr) 2018-11-13 2020-05-22 Biotheryx, Inc. Isoindolinones substituées
SG11202105084VA (en) 2018-11-16 2021-06-29 Juno Therapeutics Inc Methods of dosing engineered t cells for the treatment of b cell malignancies
JP2022513685A (ja) 2018-11-30 2022-02-09 ジュノー セラピューティクス インコーポレイテッド 養子細胞療法を用いた処置のための方法
CN113453679A (zh) 2018-12-20 2021-09-28 C4医药公司 靶向蛋白降解
US20220096651A1 (en) 2019-01-29 2022-03-31 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1)
EP3935050A4 (fr) 2019-03-06 2023-01-04 C4 Therapeutics, Inc. Composés hétérocycliques pour traitement médical
CA3208313A1 (fr) 2021-01-13 2022-07-21 Monte Rosa Therapeutics Ag Composes d'isoindolinone
WO2023220641A2 (fr) 2022-05-11 2023-11-16 Juno Therapeutics, Inc. Méthodes et utilisations associées à une thérapie par lymphocytes t et leur production
WO2023220655A1 (fr) 2022-05-11 2023-11-16 Celgene Corporation Méthodes pour surmonter la résistance aux médicaments par ré-sensibilisation de cellules cancéreuses à un traitement avec une thérapie antérieure par l'intermédiaire d'un traitement avec une thérapie par lymphocytes t
WO2023250400A1 (fr) 2022-06-22 2023-12-28 Juno Therapeutics, Inc. Méthodes de traitement pour thérapie de deuxième ligne par cellules car-t ciblées par cd19

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3378763D1 (en) * 1982-04-02 1989-02-02 Takeda Chemical Industries Ltd Condensed pyrrolinone derivatives, and their production
CA1284647C (fr) * 1986-12-25 1991-06-04 Kazuhiro Kubo Derive d'isoindolin-1-one et agent anti-arythmie
US4808402A (en) * 1987-05-29 1989-02-28 Northwestern University Method and compositions for modulating neovascularization
DK24089D0 (da) * 1989-01-20 1989-01-20 Hans Bundgaard Novel prodrug derivatives of biologically active agents containing hydroxyl groups or nh-acidic groups
GB9109645D0 (en) 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
WO1992014455A1 (fr) * 1991-02-14 1992-09-03 The Rockefeller University PROCEDE POUR LIMITER LES CONCENTRATIONS ANORMALES DE TNF-α DANS LES TISSUS CHEZ L'HOMME
ES2098505T3 (es) * 1991-04-17 1997-05-01 Gruenenthal Chemie Nuevos derivados de la talidomida, su procedimiento de preparacion y composiciones farmaceuticas que los contienen.
US6228879B1 (en) * 1997-10-16 2001-05-08 The Children's Medical Center Methods and compositions for inhibition of angiogenesis
US20010056114A1 (en) * 2000-11-01 2001-12-27 D'amato Robert Methods for the inhibition of angiogenesis with 3-amino thalidomide
US5629327A (en) * 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
US5698579A (en) * 1993-07-02 1997-12-16 Celgene Corporation Cyclic amides
US5463063A (en) * 1993-07-02 1995-10-31 Celgene Corporation Ring closure of N-phthaloylglutamines
DE4422237A1 (de) * 1994-06-24 1996-01-04 Gruenenthal Gmbh Verwendung von Lactamverbindungen als pharmazeutische Wirkstoffe
US5795368A (en) * 1996-03-01 1998-08-18 O.I. Corporation Microtrap sample concentrator and methods of use
DE19613976C1 (de) * 1996-04-09 1997-11-20 Gruenenthal Gmbh Thalidomid-Prodrugs mit immunmodulatorischer Wirkung
US6281230B1 (en) * 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
US5798368A (en) * 1996-08-22 1998-08-25 Celgene Corporation Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels
HU228769B1 (en) * 1996-07-24 2013-05-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
US5635517B1 (en) * 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
EP2070920B8 (fr) * 1996-07-24 2011-04-27 Celgene Corporation 2-(2,6-dioxopipéridin-3-yl)-phtalimides et 1-oxoisoindolines substituées et procédé pour réduire les niveaux de TNF alpha
DE69739181D1 (de) * 1996-08-12 2009-02-05 Celgene Corp Neue immunotherapeutische Mittel und deren Verwendung in der Reduzierung von Cytokinenspiegel
ES2253787T3 (es) * 1996-11-05 2006-06-01 The Children's Medical Center Corporation Composiciones para inhibicion de la angiogenesis que comprenden talidomida y un nsaid.
US5955476A (en) * 1997-11-18 1999-09-21 Celgene Corporation Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels
US5874448A (en) * 1997-11-18 1999-02-23 Celgene Corporation Substituted 2-(2,6 dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing TNFα levels
TR200101503T2 (tr) * 1998-03-16 2002-06-21 Celgene Corporation 2-(2,6-dioksopiperidin-3-il) izoindolin türevleri, bunların hazırlanması ve enflamatuar sitokinlerin inhibitörleri olarak kullanımı
US6673828B1 (en) * 1998-05-11 2004-01-06 Children's Medical Center Corporation Analogs of 2-Phthalimidinoglutaric acid
DE60014603T2 (de) * 1999-03-12 2006-02-16 Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield Heterocyklischer harnstoff und verwandte verbindungen als entzündungshemmende mittel
AU771015B2 (en) * 1999-03-18 2004-03-11 Celgene Corporation Substituted 1-oxo- and 1,3-dioxoisoindolines and their use in pharmaceutical compositions for reducing inflammatory cytokine levels
US7182953B2 (en) * 1999-12-15 2007-02-27 Celgene Corporation Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
WO2001074362A1 (fr) * 2000-03-31 2001-10-11 Celgene Corporation Inhibition de l'activite de l'enzyme cyclooxygenase-2
US6458810B1 (en) * 2000-11-14 2002-10-01 George Muller Pharmaceutically active isoindoline derivatives
JP4242651B2 (ja) 2000-11-30 2009-03-25 ザ チルドレンズ メディカル センター コーポレイション ４−アミノ−サリドマイドエナンチオマーの合成法
US20030045552A1 (en) * 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
US7091353B2 (en) * 2000-12-27 2006-08-15 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
EP1389203B8 (fr) * 2001-02-27 2010-03-10 The Governement of the United States of America, represented by The Secretary Department of Health and Human services Analogues de thalidomide utilises comme inhibiteurs de l'angiogenese
US7153867B2 (en) * 2001-08-06 2006-12-26 Celgene Corporation Use of nitrogen substituted thalidomide analogs for the treatment of macular degenerator
JP2005536189A (ja) 2002-04-12 2005-12-02 セルジーン・コーポレーション 血管新生のモジュレーターの同定方法、それにより見出された化合物および該化合物を使用する治療方法
US7498171B2 (en) * 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
WO2003097052A2 (fr) 2002-05-17 2003-11-27 Celgene Corporation Methodes et compositions faisant appel a des composes immunomodulateurs pour le traitement et la prise en charge des cancers et d'autres maladies
US7323479B2 (en) 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
US7968569B2 (en) 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
US7189740B2 (en) 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
KR20050057672A (ko) 2002-10-24 2005-06-16 셀진 코포레이션 통증의 치료, 변형 및 관리를 위한 면역조절 화합물을포함하는 조성물 및 이의 사용 방법
US20050203142A1 (en) * 2002-10-24 2005-09-15 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
CA2504024A1 (fr) 2002-10-31 2004-05-21 Celgene Corporation Compositions comprenant des composes immunomodulateurs pour le traitement et la gestion d'une degeneration maculaire, ainsi que leurs methodes d'utilisation
US20040091455A1 (en) 2002-10-31 2004-05-13 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration
US7563810B2 (en) 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
UA83504C2 (en) * 2003-09-04 2008-07-25 Селджин Корпорейшн Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
US20050100529A1 (en) 2003-11-06 2005-05-12 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
CN1913896B (zh) * 2003-12-02 2010-12-01 细胞基因公司 用于治疗和控制血红蛋白病和贫血病的方法和组合物
US20050143344A1 (en) * 2003-12-30 2005-06-30 Zeldis Jerome B. Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases
CN1956718A (zh) * 2004-03-22 2007-05-02 细胞基因公司 用于治疗和控制皮肤疾病和病症的含免疫调节化合物的组合物和使用方法
US20050222209A1 (en) 2004-04-01 2005-10-06 Zeldis Jerome B Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease
MXPA06011798A (es) 2004-04-14 2007-01-16 Celgene Corp Metodos de uso y composiciones que comprenden compuestos inmunomoduladores para el tratamiento y manejo de sindromes mielodisplasticos.
BRPI0510110A (pt) 2004-04-23 2007-09-25 Celgene Corp método para tratar, prevenir ou controlar hipertensão pulmonar, e, composição farmacêutica
CN1984657B (zh) 2004-05-05 2010-12-15 细胞基因公司 用于治疗和控制骨髓增生性疾病的包含免疫调节化合物的组合物和使用方法

Also Published As

Publication number Publication date
JP4307567B2 (ja) 2009-08-05
AU7701298A (en) 1998-12-30
JP2009138009A (ja) 2009-06-25
WO1998054170A1 (fr) 1998-12-03
EP0984955A1 (fr) 2000-03-15
CN1258293A (zh) 2000-06-28
NO2012004I1 (no) 2012-03-19
DK0984955T3 (da) 2005-01-03
DE69839739D1 (de) 2008-08-28
NZ501429A (en) 2001-11-30
TR200801878T2 (tr) 2008-08-21
CZ427899A3 (cs) 2000-05-17
KR100526212B1 (ko) 2005-11-03
NO332271B1 (no) 2012-08-13
HU228769B1 (en) 2013-05-28
CN1911927A (zh) 2007-02-14
HU229578B1 (en) 2014-02-28
NO331367B1 (no) 2011-12-12
RU2209207C2 (ru) 2003-07-27
ES2309443T3 (es) 2008-12-16
NO20120330L (no) 2000-01-28
DE69825994D1 (de) 2004-10-07
EP1956017B1 (fr) 2013-01-23
PL337124A1 (en) 2000-07-31
HUP0003217A3 (en) 2002-03-28
NO20061455L (no) 2000-01-28
ATE275139T1 (de) 2004-09-15
NO20092860L (no) 2000-01-28
FI19992490A (fi) 2000-01-27
SK163099A3 (en) 2000-06-12
ES2229497T3 (es) 2005-04-16
DE69825994T2 (de) 2005-09-29
CA2291218A1 (fr) 1998-12-03
NO995751D0 (no) 1999-11-23
US7459466B2 (en) 2008-12-02
NO322080B1 (no) 2006-08-14
CN1680367A (zh) 2005-10-12
US6395754B1 (en) 2002-05-28
HUP0003217A2 (hu) 2001-06-28
PT1486496E (pt) 2008-07-30
NO332270B1 (no) 2012-08-13
NO333641B1 (no) 2013-07-29
NO20111536L (no) 2000-01-28
HUP9903929A3 (en) 2004-04-28
TR200000107T2 (tr) 2000-07-21
CA2669481C (fr) 2011-10-04
TR200500299T2 (tr) 2005-06-21
TR201005282T2 (tr) 2011-06-21
KR20010013097A (ko) 2001-02-26
PL193276B1 (pl) 2007-01-31
EP1956017A1 (fr) 2008-08-13
PT984955E (pt) 2005-01-31
US20050131024A1 (en) 2005-06-16
ES2403102T3 (es) 2013-05-14
CZ299812B6 (cs) 2008-12-03
JP2002501536A (ja) 2002-01-15
CA2291218C (fr) 2009-10-13
EP1486496A1 (fr) 2004-12-15
EP1486496B1 (fr) 2008-07-16
US20020173658A1 (en) 2002-11-21
HUP9903929A2 (hu) 2000-05-29
DK1486496T3 (da) 2008-09-08
CA2669481A1 (fr) 1998-12-03
NO2012004I2 (no) 2013-05-06
NO995751L (no) 2000-01-28
ATE401319T1 (de) 2008-08-15
MC225A7 (fr) 2006-03-07
AU741982B2 (en) 2001-12-13
CY1108348T1 (el) 2014-02-12
EP0984955B1 (fr) 2004-09-01

Similar Documents

Publication Publication Date Title
HK1072248A1 (en) Substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimides and method of reducing tnf alpha levels
CA2247443A1 (fr) Derives d'acide 4-hydroxy-phenylalcanoique substitue possedant une activite agoniste envers ppar-gamma
HK1072770A1 (en) Bicyclic compound
TR199601032A2 (tr) Matris metalloprotaz önleyicileri.
TW290546B (fr)
ES2105108T3 (es) Esteroides para el tratamiento de la hipertrofia prostatica, su preparacion y su utilizacion.
EA200000614A1 (ru) 2,3-замещенные соединения индола в качестве ингибиторов сох-2
CA2012503A1 (fr) Composes renfermant un anti-u.v. et des portions de molecule a base d'amines encombrees steriquement par un groupement 1-hydrocarbyloxy et compositions stabilisees
IE890177L (en) Piperidinyl derivatives
NO944926L (no) Fremgangsmåter for å inhibere myeloperoksidaseaktivitet
NO972887L (no) Piperidineddiksyrederivater anvendelige som fibrinogen-antagonistmiddel
AP9901578A0 (en) Sulfonylbenzene compounds as anti-inflammatory/analgesic agents.
TW226015B (fr)
TW197420B (fr)
MY109517A (en) Carboxylic acid derivatives
WO1991000729A3 (fr) Bis-dioxopiperazines, et leur utilisation en tant qu'agents de protection
SE8800863D0 (sv) 3-(2-haloethyl)-1,4-oxathiins and 2-(2-haloethyl)-1,4-dithiins and treatment of leukemia and tumors therewith
EP1120415A4 (fr) Composes d'isoxazolylthiophene substitue
GR3002594T3 (en) Aromatic thioethers
NO973103L (no) Fremgangsmåte for inhibering av veksthormoneffekter
DE69108225D1 (en) Thioformamidderivate.
MX9702941A (es) Compuestos de di-ter - butilfenol que tiene una porcion heterociclica, utiles como agentes anti-inflamatorios.

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20160528